Related Experiment Video
Updated: May 4, 2026

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
Published on: July 8, 2020
Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition
Background:
Mammalian target of rapamycin (mTOR) inhibitors are associated with dermatological adverse events. The chief aim of this study was to examine the relation between the signal transducer and activator of transcription 3 (STAT3) protein and the dermatological adverse events associated with the mTOR inhibitor everolimus.
Methods:
We evaluated the effects of STAT3 activity and related signal transduction activities on everolimus-induced cell growth inhibition in the human keratinocyte HaCaT cell line via a WST-8 assay, and on signal transduction mechanisms involved in everolimus treatments via a western blot analysis. Apoptosis was evaluated using an imaging cytometric assay.
Results:
The cell growth inhibitory effects of everolimus were enhanced by stattic or STA-21, which are selective inhibitors of STAT3, treatment in HaCaT cells, although such effects were not observed in Caki-1 and HepG2 cells. Phosphorylation at tyrosine 705 of STAT3 was decreased by treatment with everolimus in a dose-dependent manner in HaCaT cells; in contrast, phosphorylation at serine 727 was not decreased by everolimus, but slightly increased. Furthermore, we found that pretreatment of p38 MAPK inhibitor and transfection with constitutively active form of STAT3 in HaCaT cells resisted the cytostatic activity of everolimus.
Conclusions:
These findings suggest that STAT3 activity may be a biomarker of everolimus-induced dermatological toxicity.
Insights
Signal transducer and activator of transcription 3 (STAT3) activity may predict skin side effects from the mTOR inhibitor everolimus. Inhibiting STAT3 enhanced everolimus
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Mammalian target of rapamycin (mTOR) inhibitors can cause skin issues.
- Everolimus, an mTOR inhibitor, is linked to dermatological adverse events.
- The role of signal transducer and activator of transcription 3 (STAT3) in these events is unclear.
Purpose of the Study:
- To investigate the relationship between STAT3 protein and everolimus-induced dermatological adverse events.
- To explore STAT3's role in everolimus's effects on keratinocytes.
Main Methods:
- Utilized WST-8 and western blot analyses to assess everolimus effects on HaCaT cells.
- Investigated STAT3 activity, cell growth inhibition, and apoptosis.
- Examined the impact of STAT3 inhibitors (stattic, STA-21) and p38 MAPK inhibitor.
Main Results:
- STAT3 inhibition enhanced everolimus's cell growth inhibitory effects in HaCaT cells.
- Everolimus decreased STAT3 phosphorylation at tyrosine 705 in HaCaT cells.
- STAT3 activation and p38 MAPK inhibition partially resisted everolimus's cytostatic activity.
Conclusions:
- STAT3 activity may serve as a predictive biomarker for everolimus-induced dermatological toxicity.
- Understanding STAT3 signaling is crucial for managing everolimus side effects.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

